The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review

R L van der Horst*, O van der Hel, L Lutgens, M van der Aa, B Slangen, R Kruitwagen, R I Lalisang

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. Treatment of FIGO I-II UCS usually consists of surgery with or without adjuvant treatment. Due to the high metastatic potential, aggressive combined modality adjuvant treatment approaches, consisting of chemo- and radiotherapy, have been of interest. Our systematic review aims to compare survival, disease control and toxicity profiles in patients receiving adjuvant chemoradiation to other adjuvant strategies (e.g.observation, chemotherapy or radiotherapy). A total of ten studies were included for a combined cohort size of 6520 patients. Generally, the studies showed a trend towards improved disease control and survival in patients undergoing adjuvant multimodal treatment, although statistical significance was often not reached. Selection bias and non-randomized treatment allocation pose serious challenges to extrapolate these outcomes to clinical practice. We recommend additional prospective research on the role of adjuvant chemoradiation in FIGO I-II UCS.

Original languageEnglish
Article number103701
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume175
Early online date6 May 2022
DOIs
Publication statusPublished - Jul 2022

Keywords

  • Adjuvant chemoradiation
  • Adjuvant multimodal treatment
  • ENDOMETRIAL CANCER
  • Early stage high risk uterine malignancy
  • FEMALE GENITAL-TRACT
  • MESODERMAL TUMORS
  • MIXED MULLERIAN TUMORS
  • PELVIC IRRADIATION
  • PHASE-II
  • PROGNOSTIC-FACTORS
  • RADIATION-THERAPY
  • STAGE-I
  • UTERINE CARCINOSARCOMA
  • Uterine carcinosarcoma
  • Uterine mixed mullarian tumor

Cite this